News of Note—Lonza adds API lines for AstraZeneca; Biocon gets EU OK

stock market prices
(Pixabay)

> Lonza is adding two lines at its site in Visp, Switzerland, for production of highly potent APIs as part of a supply deal with AstraZeneca. Release

> Indian biosimilar maker Biocon says its biologics drug product facility and its drug substance facility in Bengaluru were approved by the European Medicines Agency following a March inspection. Release

> AptarGroup in Crystal Lake, Illinois, is spending about $50 million to buy pharmaceutical services companies Nanopharm and Gateway Analytical to expand its offerings to the biopharma industry. Release

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The Medicines and Healthcare products Regulatory Agency in the U.K. is recalling two batches of 500 mg paracetamol tablets produced by M&A Pharmachem because of discoloration caused by fungi. Stor

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.